ADX-102 Ophthalmic Solution (0.5%)
ADX-102-DES-007
Phase 2 small_molecule completed
Quick answer
ADX-102 Ophthalmic Solution (0.5%) for Dry Eye Syndromes is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Dry Eye Syndromes
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed